Viral
bronchiolitis is
an inflammatory disorder which is characterized by obstruction of small
airways, necrosis and edema of the epithelial cells, and increased mucus
production. The disease is most commonly caused by an infection caused by
respiratory syncytial virus.
Access
Detailed Report Summary:
The signs
and symptoms observed in the patients are low grade fever, congestion, and
apnea. However, in most severe cases, respiratory distress, cyanosis, and
irritability also occurs in the patients. Viral bronchiolitis is the most
common illness observed in children in their first two years of life.
Request
to Get the Sample Pages at:
Ait
Therapeutics Inc. is in the process of developing AIT-RSV as a guanylate
cyclase stimulant for the treatment of viral bronchiolitis. Some of the other
companies and universities having pipeline drugs for viral bronchiolitis
include Washington University School of Medicine, and Vaxart Inc.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment